Merck's Support for Ukraine
Originally published on LinkedIn
Merck has a 130 year plus legacy of saving and improving lives around the world, and we remain committed to doing so. We are saddened by the invasion of Ukraine and stand united with the Ukrainian people who face a humanitarian crisis resulting from this conflict. Our hope is for a quick and peaceful resolution, and our paramount concerns are the safety and well-being of our employees, and ensuring our patients and customers have continued access to our medicines and vaccines.
During this time of tragedy, our commitment to helping the people affected is unwavering. We are using our resources to help alleviate the human suffering in Ukraine. To date, we have delivered 135,000 courses of molnupiravir through a supply and purchase agreement with the government and donated 100,000 courses of molnupiravir to Direct Relief, an organization providing emergency medical assistance. We have also committed $1 million in support of aid organizations, including $300,000 to the American Red Cross, delivering urgent assistance.
We will continue to monitor this tragedy and update our response as this crisis unfolds. Our focus now remains on doing what we can to ensure access to our medicines and vaccines, and further using our resources to alleviate the unimaginable human suffering in Ukraine. merck.us/3KoNdBT
About Merck
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Learn more about the company’s commitment to diversity and inclusion in their Environmental, Social and Governance (ESG) Progress Report.
View original content here.
